LexAurum Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.95M | Buy |
2,463
+9
| +0.4% | +$9.2K | 0.34% | 62 |
|
|
2026
Q1 | $2.26M | Buy |
+2,454
| New | +$2.49M | 0.29% | 67 |
|
|
2025
Q3 | $2.38M | Buy |
3,121
+2,003
| +179% | +$1.49M | 0.34% | 57 |
|
|
2025
Q2 | $872K | Sell |
1,118
-41
| -4% | -$31.9K | 0.14% | 130 |
|
|
2025
Q1 | $957K | Sell |
1,159
-4
| -0.3% | -$3.33K | 0.18% | 118 |
|
|
2024
Q4 | $898K | Buy |
1,163
+85
| +8% | +$70.4K | 0.18% | 115 |
|
|
2024
Q3 | $955K | Sell |
1,078
-20
| -2% | -$18K | 0.21% | 101 |
|
|
2024
Q2 | $994K | Sell |
1,098
-231
| -17% | -$185K | 0.24% | 92 |
|
|
2024
Q1 | $1.03M | Sell |
1,329
-221
| -14% | -$157K | 0.26% | 85 |
|
|
2023
Q4 | $904K | Buy |
1,550
+130
| +9% | +$75.9K | 0.24% | 95 |
|
|
2023
Q3 | $763K | Sell |
1,420
-674
| -32% | -$347K | 0.22% | 100 |
|
|
2023
Q2 | $982K | Buy |
2,094
+409
| +24% | +$172K | 0.3% | 72 |
|
|
2023
Q1 | $579K | Buy |
1,685
+306
| +22% | +$103K | 0.19% | 112 |
|
|
2022
Q4 | $504K | Sell |
1,379
-20
| -1% | -$7.09K | 0.18% | 118 |
|
|
2022
Q3 | $452K | Sell |
1,399
-7
| -0.5% | -$2.22K | 0.17% | 126 |
|
|
2022
Q2 | $456K | Sell |
1,406
-226
| -14% | -$67.8K | 0.17% | 123 |
|
|
2022
Q1 | $467K | Sell |
1,632
-2
| -0.1% | -$515 | 0.15% | 132 |
|
|
2021
Q4 | $451K | Sell |
1,634
-78
| -5% | -$19.8K | 0.15% | 150 |
|
|
2021
Q3 | $396K | Hold |
1,712
| – | – | 0.12% | 196 |
|
|
2021
Q2 | $393K | Hold |
1,712
| – | – | 0.12% | 191 |
|
|
2021
Q1 | $320K | Sell |
1,712
-319
| -16% | -$62.4K | 0.11% | 192 |
|
|
2020
Q4 | $343K | Hold |
2,031
| – | – | 0.12% | 177 |
|
|
2020
Q3 | $301K | Sell |
2,031
-33
| -2% | -$5.11K | 0.12% | 163 |
|
|
2020
Q2 | $339K | Sell |
2,064
-126
| -6% | -$19.3K | 0.19% | 124 |
|
|
2020
Q1 | $304K | Hold |
2,190
| – | – | 0.21% | 107 |
|
|
2019
Q4 | $288K | Hold |
2,190
| – | – | 0.14% | 160 |
|
|
2019
Q3 | $245K | Hold |
2,190
| – | – | 0.15% | 158 |
|
|
2019
Q2 | $243K | Sell |
2,190
-6
| -0.3% | -$707 | 0.15% | 140 |
|
|
2019
Q1 | $285K | Hold |
2,196
| – | – | 0.19% | 121 |
|
|
2018
Q4 | $254K | Buy |
2,196
+117
| +6% | +$13.1K | 0.2% | 119 |
|
|
2018
Q3 | $223K | Buy |
+2,079
| New | +$208K | 0.16% | 134 |
|
|
2018
Q1 | – | Sell |
-2,653
| Closed | -$231K | – | 157 |
|
|
2017
Q4 | $231K | Buy |
+2,653
| New | +$226K | 0.22% | 124 |
|
Other funds holding LLY
SC
ONB
GIM
LexAurum Advisors's LLY Position: Q2 2026 in Review
LexAurum Advisors increased its Eli Lilly (LLY) stake by 0.37% in Q2 2026, buying an estimated $9.2K and bringing the position to 2,463 shares worth $2.95M. The position accounts for 0.34% of the portfolio, ranked #62.
LexAurum Advisors first reported a position in LLY in Q4 2017 and has held it in 32 quarters since. 1,857 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- LexAurum Advisors held 2,463 shares of Eli Lilly worth $2.95M as of Q2 2026.
- LexAurum Advisors bought 9 Eli Lilly shares in Q2 2026, an estimated $9.2K.
- Eli Lilly made up 0.34% of LexAurum Advisors's portfolio in Q2 2026, its #62 holding.
- LexAurum Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 32 quarters since.
- 1,857 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on LexAurum Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.